KRAS and cancer: A phylogenetic analysis of the somatic mutations and CNAs of the index patient suggested that the brain metastatic lesions diverged from the primary tumor and acquired additional likely pathogenic mutations in the cancer genes FGFR2, PIK3CA and ATR, homozygous deletion in CDKN2A and amplification in KRAS (Figure 1E).